Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New vaccine protects more effectively against tuberculosis

Max Planck Society : 15 November, 2006  (New Product)
The team of Prof. Stefan H.E. Kaufmann at the Max Planck Institute for Infection Biology in Berlin has designed a novel tuberculosis vaccine with high vaccine efficacy. The vaccine has been licensed to the Vakzine Projekt Management who will test it in clinical trials. The responsible mechanisms for the high efficacy of this vaccine has now been deciphered.
The team of Prof. Stefan H.E. Kaufmann at the Max Planck Institute for Infection Biology in Berlin has designed a novel tuberculosis vaccine with high vaccine efficacy. The vaccine has been licensed to the Vakzine Projekt Management who will test it in clinical trials. The responsible mechanisms for the high efficacy of this vaccine has now been deciphered.

Globally, tuberculosis remains the number one killer in adults. Moreover, multi-drug-resistant tuberculosis strains are on the rise which cannot be treated by first-line drugs. A vaccine against tuberculosis, termed BCG is available which, however, fails to protect against the most frequent form of disease, pulmonary tuberculosis in adults. A more efficient vaccine is urgently needed for control of this global threat.

Recombinant BCG, which express listeriolysin and is deleted for the urease gene, has been created and shown to stimulate far more efficacious protection against tuberculosis than the BCG vaccine currently in use. This new vaccine induces cell death in infected host cells, which leads to stimulation of protection by dendritic cells, the most efficacious antigen-presenting cells. As a result, stronger protection against pulmonary tuberculosis has been achieved in preclinical studies. Importantly, the new vaccine also protects against clinical isolates of the Beijing family. These clinical isolates are frequently multi-drug-resistant and more aggressive and hence have started to conquer the globe. It has been assumed that the Beijing isolates emerged in response to drug treatment and vaccination. The new genetically engineered BCG could provide an efficacious measure against this threat.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo